The GFAP/NfL ratio does not outperform NfL or GFAP in genetic frontotemporal dementia
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)
DOI: 10.1002/dad2.70483 ↗Abstract
Abstract INTRODUCTION We investigated the diagnostic utility of the plasma glial fibrillary acidic protein (GFAP)/neurofilament light chain (NfL) ratio in genetic frontotemporal dementia (FTD) and compared its performance with GFAP and NfL alone. METHODS Baseline plasma samples were available from 391 pathogenic variant carriers and non‐carriers, with longitudinal samples (≥2) from 259 participants. Linear mixed‐effects models were used to assess baseline differences between clinical groups, longitudinal trajectories, and the ability of the GFAP/NfL ratio to discriminate underlying TAR DNA‐binding protein (TDP) versus tau pathology. RESULTS Baseline GFAP/NfL ratios differed across clinical groups; however, the ratio did not outperform GFAP or NfL alone in any clinically relevant comparison. No significant differences were observed between symptomatic carriers with underlying TDP versus tau pathology. DISCUSSION The GFAP/NfL ratio provides no added value over NfL alone as a diagnostic or susceptibility biomarker in genetic FTD.
EUVIMED